Web-Site-InteriorPage-Graphics-provider-news

Physician-administered drugs updates for providers

Provider Icon

Please review the following information on physician-administered drugs (PADs) changes and Alliance preferred PADs. Note: these updates are for Medi-Cal and IHSS only.

For more information on physician-administered drugs, including criteria and policies, please visit our website:

PADs changes effective September 1, 2026

The Alliance has made changes to physician-administered drug benefits. You can find prior authorization (PA) criteria on our website.

The changes are as follows:

HCPCS Code Drug Change Preferred Drug
J9053 Belantamab mafodotin (Blenrep) PA required n/a
J9003 Camcevi ETM New PA criteria n/a
J2361 Depemokimab (Exdensur) New PA criteria Dupixent (dupilumab),

Fasenra (benralizumab),

Nucala (mepolizumab), or

Tezspire (Tezepelumab-ekko)

Q5154 Omalizumab-igec (Omlyclo) Modified PA criteria Dependent on diagnosis:

·         Inhaled corticosteroids (asthma).

·         High dose antihistamine (chronic spontaneous urticaria).

·         Nasal corticosteroid (chronic rhinosinusitis with nasal polyps).

J2357 Omalizumab (Xolair)
J7318 Durolane Modified PA criteria Acetaminophen, NSAID and two intra-articular steroid injections
J7320 Genvisc 850
J7321 Hyalgan, Supartz, Supartz FX,  Visco-3
J7322 Hymovis, Hymovis One
J7323 Euflexxa
J7324 Orthovisc
J7325 Synvisc, Synvisc-One
J7326 Gel-One
J7327 Monovisc
J7328 Gelsyn-3
J7329 Trivisc

 

The Alliance has updated the following pharmacy policies:

To request a copy, please call the Alliance Pharmacy Department at 831-430-5507.